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Linezolid showed higher activity (MICgo 4.0 mg/L) 
against B. jragilis (100 strains) compared to eperezolid 
(MICgo 16 mg/L). The MIC values (range, MIC50 and 
MICgo) for the 360 tested strains of linezolid and 
eperezolid are shown in Table 1. Strains with intrinsic 
resistance to conventional anti-anaerobe agents, includ- 
ing three C. d@le strains and one B. jagi l i s  strain 
resistant to clindamycin, seven €3. ,%@is strains resistant 
to cefoxitin, and one B. splunchnicus resistant to 
metronidazole, did not show any cross-resistance to the 
oxazolidinones. 
The results of the present study are in accordance 
with previous reports on in vitro susceptibility to 
linezolid and eperezolid of anaerobic microorganisms 
[3].  Oral administration of linezolid (400 mg PO) and 
eperezolid (1 000 mg PO) to healthy volunteers has 
earlier been reported to yield peak serum concentra- 
tions of 12.38 mg/L and 6.28 mg/L, respectively, while 
the trough concentrations were estimated to be 
7.9 mg/L and 1.62 mg/L, respectively [7]. These serum 
levels of linezolid are well in excess of the MICs €or 
anaerobic Gram-positive bacteria as well as for many 
anaerobic Gram-negative microorganisms. Concerning 
eperezolid, anaerobic Gran-positive bacteria are mainly 
susceptible to achieved serum levels. Linezolid has 
been reported to be active versus experimental B. -fiagilis 
soft tissue infections in mice [XI .  Future clinical studies 
will show the potential of the oxazolidinones in 
the treatment of anaerobic infections. In conclusion, 
the new oxazolidinones linezolid and eperezolid 
have excellent activity against Gram-positive anaerobic 
microorganisms, with linezolid also exhibiting activity 
against Bacteroides spp. These agents may be useful in 
the treatment and prophylaxis of anaerobic infections. 
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Agglutination kits for the identification of Staphylococcus 
aweus have been available for a number of years as an 
alternative to the coagulase test. The tube coagulase 
test, which detects the production of free coagulase, 
was considered to be the standard (sensitivity 95-98%) 
but it takes 4-34 h for completion [I 4. A more simple 
5 4  C l in ica l  M i c r o b i o l o g y  a n d  I n f e c t i o n ,  V o l u m e  5 N u m b e r  1, J a n u a r y  1999 
and widely used test is the detection ofbound coagulase 
(clumping factor) by a slide agglutination reaction. 
However, this test is less reliable and has a 10-15% false- 
negative rate [l]. Rapid commercial agglutination assays 
based on the detection of clumping factor and protein 
A became available in the early 1980s, and reports 
suggested accuracy similar to that of the tube coagulase 
test [3-51. However, later reports documented false- 
negative results among methicillin-resistant S. uureus 
(MRSA) strains, and this has been explained by the 
absence or low-level production of clumping factor or 
protein A in some strains [6-111. More recently, some 
kits have been enhanced to overcome the problems 
with identification of MRSA by including antibodies 
to cell surface antigens or capsular polysaccharide, and 
it is reported that some kits have proved reliable for the 
identification of MRSA [12-151. These reports suggest 
that the kits have a sensitivity of 96.9-100%. However, 
it is unclear how well these new kits perform with 
epidemic strains of MRSA (EMRSA) described in the 
UK, and what their reliability is for the identification 
of strains of MRSA which gave problems with the 
earlier kit formulations. 
MRSA strains were detected soon after the intro- 
duction of methicillin in 1960 [16]. Reports of their 
isolation increased in the UK up to a peak of 5% of 
strains sent to the Staphylococcus Reference Laboratory 
in 1971 [17]. There followed a fall in the number of 
isolations of MRSA in the UK and some European 
countries which has been suggested to be due to the 
increased use of aminoglycosides [18]. However, in the 
1980s there was the recognition of strains described 
as ‘epidemic’ on the basis of their particular ability to 
spread and cause infection, while other strains do not 
behave in this way [19]. EMRSA is defined as affecting 
two or more patients in two or more hospitals [20]. 
EMRSA strains were characterized on the basis ofphage 
typing, antibiogram, protein A and urease production 
and the presence of toxins. EMRSA-1 was first detected 
in 198 1 and became progressively more widespread, 
particularly in the Thames regions, until it began to 
decline in 1987. Further epidemic strains were described 
during the late 1980s, and Kerr et a1 described 14 
different EMRSA strains in 1990 [21]. The majority 
of the EMRSA strains have been associated with out- 
breaks restricted to specific areas of the UK. For 
example, EMRSA-2 has remained restricted to the 
South East and South West Thames regions [17]. 
However, some strains have spread throughout a 
number of regions and have affected multiple hospitals. 
These strains include EMRSA-3 (phage type 75/83A), 
EMRSA-15 (phage type 75) and EMRSA-16 (phage 
type 29/52/75/77/83A). Currently, EMRSA-3 is the 
third most common epidemic strain reported and its 
incidence has remained steady [22 ] .  It appeared in the 
South East Thames region in 1987 and is affecting 
between 10 and 15 hospitals a month. In contrast, the 
incidence of strains EMRSA-15 and EMRSA-16 has 
continued to increase during the period 1993-97, and 
they currently affect approximately 135 and 125 hospitals 
a month respectively [22]. Isolates of EMRSA-15 have 
been reported predominantly from the West Midlands 
Table 1 Identification of methicillin-resistant S. uureux by tube coagulase and latex agglutination kits 
EMRSA 
- Method Antigen detected + 
~ 
Other MRSA 
Tube coagulase Free coagulase 64 
Slidex Staph Clumping factor 
Protein A 
Cell surface antigen 
Staphaurex Plus Clumping factor 
Protein A 
Cell surface antigen 
Staphytect Plus Clumping factor 
Protein A 
Capsular polysaccharide 
Prolex Staph Clumping factor 
Protein A 
64 
64 
64 
64 
Pastorex Staph-Plus Clumping factor 64 
Protein A 
Capsular polysaccharide 
0 
0 
11 0 
8 3 
8 
11 
7 4 
8 3 
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and North Thames, while EMRSA-16 has been con- 
centrated in the Thames regions, although both have 
been isolated throughout the UK. 
The epidemic strains have been associated with 
dfferent infections. EMRSA-3, which is more common 
in the community, is often isolated from pressure 
sores and ulcers [23]. EMRSA-15 appears to colonize 
patients in care of the elderly units and is often isolated 
from eyes, pressure sores, vaginal swabs and urine [24]. 
EMRSA-16 tends to be established in hospitals, causing 
a variety of infections, particularly chest infections [25]. 
We have tested the ability of several currently 
available latex agglutination kits to recognize isolates of 
EMRSA. We have also tested the kits with strains of 
MRSA which gave problems with identification using 
earlier latex agglutination kits. Sixty-four strains of 
E M M A  were examined. These included three of type 
1, four of type 2, five of type 3, two of type 4, three of 
type 5, three of type 6, two of type 7, three of type 8, 
one of type 9, three of type 10, three of type 1 1, three 
of type 12, three of type 13, three of type 14, one 
of type 15 and two of type 16. We are grateful to 
Dr B. Cookson of the Central Public Health Labora- 
tory, London, UK for supplying these isolates, which 
were from various hospitals in the UK. Isolates of the 
same EMRSA type were from different hospitals. 
An additional 10 isolates of E M M A  type 15 and 
10 of EMRSA 16 were from different patients at 
Addenbrooke’s Hospital, Cambridge. Eleven MRSA 
strains which were not EMRSA but which caused 
problems with earlier kits were also included [7]. All 75 
strains were examined for coagulase production by the 
tube coagulase test [36] and for agglutination with five 
commercial latex kits (Slidex Staph, bioM6rieux UK 
Ltd, Basingstoke, UK; Staphaurex Plus, Murex Biotech 
Ltd, Dartford, UK; Staphytect Plus, Oxoid Ltd, 
Basingstoke, UK; Prolex Staph, Pro-Lab Diagnostics, 
Neston, UK; Pastorex Staph-Plus, Sanofi Pasteur, 
Guildford, UK). 
The identity of all strains of S. aliveus was con- 
firmed by the tube coagulase test (Table 1). All latex 
agglutination ki ts  proved reliable for the identification 
of all the EMRSA strains. However, there were problems 
with the identification of some of the strains which had 
given problems with the early agglutination kits. The 
Staphytect Plus was the only kit which was able to 
identifi all the earlier problematic strains. The Prolex 
Staph, which detects only clumping factor and protein 
A, had only one more error than three of the kits which 
include detection of other cell wall coniponents. 
Interestingly, different tests gave false-negative results 
with different strains, and eight strains gave false- 
negative results with at least one kit. This is probably 
related to deficiencies in the strains for the particular 
components detected by the individual kits. 
While all the kits correctly identified EMRSA 
strains, which account for a large proportion of the 
isolates currently causing problems in the UK, users 
should be aware of the possible limitations with some 
non-epidemic strains. 
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